Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week Low – Should You Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price hit a new 52-week low during trading on Tuesday . The company traded as low as $17.40 and last traded at $17.47, with a volume of 12685 shares. The stock had previously closed at $18.14.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on DNTH shares. Guggenheim reissued a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. TD Cowen assumed coverage on Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating on the stock. Finally, Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $54.33.

Dianthus Therapeutics Stock Performance

The firm has a market cap of $568.61 million, a PE ratio of -7.07 and a beta of 1.82. The firm has a fifty day simple moving average of $21.88 and a two-hundred day simple moving average of $24.17.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.40 million. Equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quest Partners LLC lifted its stake in shares of Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after purchasing an additional 1,124 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after acquiring an additional 97,362 shares during the period. MetLife Investment Management LLC lifted its holdings in shares of Dianthus Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock worth $382,000 after acquiring an additional 7,854 shares during the last quarter. Walleye Capital LLC purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter worth about $821,000. Finally, Fred Alger Management LLC grew its holdings in Dianthus Therapeutics by 52.5% during the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock valued at $264,000 after purchasing an additional 3,316 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.